RIPK1 and ptosis: The multi-targeted kinase inhibitor Ponatinib, as an antitumor agent, can also prevent necrotic ptosis by targeting RIPK1, but its lack of specificity and severe long-term adverse reactions have limited its development for the treatment of inflammatory diseases associated with RIPK1.